Randomized, double‐blind, placebo‐controlled phase 2 study of ganaxolone as add‐on therapy in adults with uncontrolled partial‐onset seizures
Epilepsia2017Vol. 58(4), pp. 558–564
Citations Over TimeTop 10% of 2017 papers
Abstract
Ganaxolone 1,500 mg/day reduced partial-onset seizure frequency and was generally safe and well tolerated in this phase 2 study. These results support continued development of ganaxolone for adult patients with refractory partial-onset seizures.
Related Papers
- → A comparison of placebo effects in clinical analgesic trials versus studies of placebo analgesia(2002)434 cited
- → Conditioned Placebo Analgesia Persists When Subjects Know They Are Receiving a Placebo(2015)116 cited
- Profile of epilepsy in Lagos, Nigeria.(1983)
- → Μελέτη της πολυπαραγοντικής αναλγησίας στο μετεγχειρητικό πόνο μετά από λαπαροσκοπική χολοκυστεκτομή(2014)
- → Ιστορική εξέλιξη της έννοιας του placebo από τα μέσα του 19ου αιώνα μέχρι σήμερα(2006)